Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Benralizumab for Eosinophilic Esophagitis
NCT04543409Phase 3Terminated
- Sponsor
- AstraZeneca
- Start
- Sep 2020
- Primary completion
- Sep 2022
- Modality
- Monoclonal Antibodies
- Countries
- 12
01
Overview
A Phase 3 trial of benralizumab in eosinophilic esophagitis (EoE), sponsored by AstraZeneca. Started Sep 2020; status: terminated.
02
Drugs
benralizumab
03
Conditions
eosinophilic esophagitis (EoE)
Beyond the preview
Go deeper on NCT04543409.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04543409.